Esperion Therapeutics' Nexletol, Nexlizet Updates Get FDA Approval
By Denny Jacob
Esperion Therapeutics received Food and Drug Administration approval for updates to nexletol and nexlizet.
The pharmaceutical company said the FDA approved an updated LDL-cholesterol lowering indication for nexletol and nexlizet to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.
Esperion said other changes include the maximally tolerated qualifier for statin use has been removed, as well as the removal of the prior limitation of use stating the effect of the two treatments on cardiovascular morbidity and mortality has not been determined.
The Ann Arbor, Mich.-based company said the labeling modifications don't impact the full pending label approvals for cardiovascular risk reduction indications for nexletol and nexlizet, which it said remains on track for anticipated approval in the first quarter.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 13, 2023 16:31 ET (21:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters